Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Shows FDA Discomfort With Meta-Analyses, Observational Studies In Decision-Making

Executive Summary

The strong, continued resistance by FDA Center for Drug Evaluation and Research officials to rely on meta-analyses and observational studies as the basis for removing Avandia from the market suggests it will take time for the agency to become comfortable using the active surveillance system envisioned under the Sentinel Initiative in regulatory decision-making.

You may also be interested in...



FDA Seeks Dedicated Meta-Analysis Team As Part Of PDUFA V User Fee Funding

FDA wants to create a meta-analysis team to conduct its own studies with funding from the next round of application user fees.

FDA Seeks Dedicated Meta-Analysis Team As Part Of PDUFA V User Fee Funding

FDA wants to create a meta-analysis team to conduct its own studies with funding from the next round of application user fees.

FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative

FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS052702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel